Fusion’s recent FY 22 results showed solid 15% growth in revenues – helped by two milestones earned from previous client projects - and a reduction in loss at the EBITDA level, despite an increased investment in R&D. Cash at the period end was £2m providing a runway well into FY24. We expect a 12% growth in revenue in FY23 with a H1:H2 split biased towards the second half of the year. We expect the new CEO to provide an impetus to sales & marketing efforts and spearhead the launch of the new Opt ....
08 Sep 2022
Fusion Antibodies Post FY22 results comment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fusion Antibodies Post FY22 results comment
Fusion Antibodies Plc (FAB:LON) | 3.8 0 0.0% | Mkt Cap: 3.58m
- Published:
08 Sep 2022 -
Author:
Robin Davison -
Pages:
5
Fusion’s recent FY 22 results showed solid 15% growth in revenues – helped by two milestones earned from previous client projects - and a reduction in loss at the EBITDA level, despite an increased investment in R&D. Cash at the period end was £2m providing a runway well into FY24. We expect a 12% growth in revenue in FY23 with a H1:H2 split biased towards the second half of the year. We expect the new CEO to provide an impetus to sales & marketing efforts and spearhead the launch of the new Opt ....